Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 5/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1900854 | 1.00 | TMEM97 (0.49) | TMEM97SIGMAR1ALDH1A1NPSR1GAA | |
| SCHEMBL10809019 | 0.81 | GAA (0.64) | TMEM97SIGMAR1ALDH1A1NPSR1GAA | |
| SCHEMBL27299616 | 0.79 | TMEM97 (0.49) | TMEM97SIGMAR1ALDH1A1NPSR1GAA | |
| SCHEMBL14375247 | 0.79 | TMEM97 (0.52) | TMEM97SIGMAR1ALDH1A1NPSR1GAA | |
| SCHEMBL3543202 | 0.76 | ALDH1A1 (0.45) | TMEM97SIGMAR1ALDH1A1NPSR1HTR1A | |
| SCHEMBL18498745 | 0.74 | ALDH1A1 (0.46) | TMEM97SIGMAR1ALDH1A1NPSR1CA2 | |
| SCHEMBL18498742 | 0.74 | ALDH1A1 (0.46) | TMEM97SIGMAR1ALDH1A1NPSR1CA2 | |
| SCHEMBL23716718 | 0.73 | TMEM97 (0.59) | TMEM97SIGMAR1ALDH1A1NPSR1GAA | |
| SCHEMBL7568260 | 0.73 | SMN1; SMN2 (0.39) | SIGMAR1ALDH1A1HSD17B10HRH3 | |
| SCHEMBL29585287 | 0.72 | TMEM97 (0.55) | TMEM97SIGMAR1ALDH1A1NPSR1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140148443-A1 | Novel Imidazolines as dual inhibitors of MDM2 and MDMX | HOFFMANN-LA ROCHE INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-8513239-B2 | Chiral cis-imidazolines | HOFFMANN-LA ROCHE INC. (US) | 2013-08-20 | — | — | US | disclosed |
| EP-2203437-B1 | CHIRAL CIS-IMIDAZOLINES | HOFFMANN LA ROCHE (CH) | 2012-11-07 | — | — | EP | disclosed |
| EP-2325180-A1 | Chiral CIS-imidazolines | F. Hoffmann-La Roche AG (CH) | 2011-05-25 | — | — | EP | disclosed |
| CN-101821251-A | Chiral cis-imidazolines | HOFFMANN LA ROCHE | 2010-09-01 | — | — | CN | disclosed |
| EP-2203437-A1 | CHIRAL CIS-IMIDAZOLINES | F. Hoffmann-Roche AG (CH) | 2010-07-07 | — | — | EP | disclosed |
| US-20090111789-A1 | CHIRAL CIS-IMIDAZOLINES | HOFFMANN-LA ROCHE, INC. | 2009-04-30 | — | — | US | disclosed |
| WO-2009047161-A1 | CHIRAL CIS-IMIDAZOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111789-A1 | CHIRAL CIS-IMIDAZOLINES | FOXM1, CCNE1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | TMEM97 3934/4885SIGMAR1 408/4885ALDH1A1 2824/4885 |
| US-20140148443-A1 | Novel Imidazolines as dual inhibitors of MDM2 and MDMX | MDM2, MDM4, TP53 | TMEM97 3563/4885SIGMAR1 3779/4885ALDH1A1 3011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.